You may remember some of the key themes we shared ahead of #ASCO24. Post-congress, our experts are reflecting back on those themes and summarizing the key insights and takeaways on these modalities from ASCO 2024. Read more & get in touch: https://lnkd.in/eHCmAX36 #CancerResearch #ADCs #RadioPharmaceuticals #Bispecifics
Putnam’s Post
More Relevant Posts
-
Merck Reports Data from the P-III (KEYLYNK-006) Study of Keytruda for Treatment of Metastatic Non-squamous NSCLC #merck #keytruda #nonsmallcelllungcancer #clinicaltrial #phase3 #metastatic #lynparza #chemotherapy #treatment #nsclc
To view or add a comment, sign in
-
CEO XCancer, Global Leader in Radiopharmaceuticals & Clinical Trials for Prostate Cancer. #19 1st-in-World/TheranosticTrials.Org/ XCancerStore.com / XCancer Foundation. XCancerMotorsports Sponsor of Thomas Nordquist F4
Making Sense of Radiopharmaceutical Ligands! Small Molecule vs Peptide vs Antibody. https://lnkd.in/gC5cmqP3 #Invenra #XCancer #Theranostics #Radiopharmaceuticals #Ligands
To view or add a comment, sign in
-
As early investors in Dyne Therapeutics, we are pleased to share they reported positive updates in their next-generation exon skipping program for Duchenne amenable to skipping exon 51. In their phase 1/2 Trial, Dyne-251 at dose of 10 mg/kg given once a month showed an average 3.2% normal dystrophin expression (7.6% normal dystrophin when adjusted for muscle content) at 6 months. Trends in functional improvements like the NSAA and other tests were observed, but non reached statistical significance at this time. Dyne-251 has fully enrolled cohorts for 20 and 40 mg/kg dosing and is reporting favorable safety profiles, while dystrophin and functional read outs for these higher doses will be coming in the future. Dyne also reported positive safety, biomarker, functional, and patient reported outcome data in Type 1 Myotonic Dystrophy program (DM1), and anticipates providing updates by the end of the year on their plans for pursuing expedited FDA approvals in both DM1 and Duchenne. #FDA #DMD #DUCHENNE #CUREDUCHENNE #CLINICALTRIALS
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
https://cureduchenne.org
To view or add a comment, sign in
-
Abdera Therapeutics launched in April 2023 with $142M in combined Series A and B financing to engineer and advance antibody-based radiopharmaceuticals for the treatment of cancer. Today, FDA has cleared its IND for ABD-147, the first precision radiopharmaceutical therapy targeting DLL3 for the treatment of small cell lung cancer and large cell neuroendocrine carcinoma. ABD-147 is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, to solid tumors expressing DLL3. DLL3 is a protein found on the surface of neuroendocrine tumors, but rarely expressed on the surface of normal cells or tissues. Trial initiation is expected in the second half of 2024.
We are excited to announce the clearance of our investigational new drug application (IND) by the U.S. FDA for ABD-147 for the treatment of small cell #lungcancer. ABD-147 is a next-generation precision #radiopharmaceutical therapy designed to deliver Actinium-225, a highly potent radioisotope, to solid tumors expressing DLL3. Learn more about our novel treatment and innovative ROVEr™ platform here: https://lnkd.in/esxvb9dQ
To view or add a comment, sign in
-
PhD Pharmacology || Jamia Hamdard (Demeed to be University) || Former Asistant Professor at Mohammad Ali Jauhar University || Teerthanker Mahaveer University Product ||
I am delighted to share that review paper titled "Diagnosing Early Hepatocellular Carcinoma: A Review" accepted and published in the reputable journal Current Pharmaceutical Design, published by Bentham Science Publishers. An impact factor of 3.1 Early detection of hepatocellular carcinoma (HCC) is crucial for curative treatment. However, initial HCC is frequently asymptomatic, necessitating screening in high-risk patients with ultrasound and alpha-fetoprotein levels. Imaging with triphasic CT or MRI aids definitive diagnosis of small lesions, though biopsy may be required when findings are indeterminate. Timely diagnosis at an early stage significantly improves prognosis and treatment options for HCC patients.
To view or add a comment, sign in
-
DelveInsight's comment: Fulzerasib emerges as a game-changer for KRAS G12C-mutated NSCLC with promising preliminary efficacy and an excellent safety profile in Phase II KROCUS Study!
GenFleet Therapeutics Fulzerasib has emerged as a strong contender in the treatment of KRAS G12C-mutated NSCLC, surpassing the efficacy of sotorasib and adagrasib. Its combination with cetuximab has shown exceptional promise, leading to plans for a Phase III trial. This highlights the potential for fulzerasib to become a key player in first-line therapy, pending further validation. Discover Expert Insights and In-Depth Analysis with DelveInsight Business Research LLP's Exclusive American Society of Clinical Oncology (ASCO) 2024 Coverage! https://lnkd.in/gQRnmPZ3 #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders
Fulzerasib Phase II KROCUS Study | ASCO 2024
delveinsight.com
To view or add a comment, sign in
-
Budget 2024: Relief for Cancer Patients and Increased PLI Allocation for Pharma The Union Budget 2024 brings some positive changes for the pharma and healthcare sectors: 🎗️ Cancer Patient Relief: Custom duties fully exempted on three AstraZeneca drugs - Trastuzumab Deruxtecan, Osimertinib, and Durvalumab. Medical Devices: Reduced basic custom duty on x-ray tubes and flat panel detectors, aiding domestic capacity addition. 📈 PLI Scheme: Increased allocation from ₹1,200 crore to ₹2,143 crore, boosting the pharma industry.
To view or add a comment, sign in
-
Senior Director @ PSI CRO | Global Late Phase Studies Oncology, Hemato-Onco, Supportive Care, IPF, Haemophilia, radiopharm, IBD, MS, anti-infectives, anti-fungals. Long-standing PCMG Assembly Steering Committee member.
#Radiopharmaceutical clinical trials face a host of logistical challenges, often leading to delays. Learn how we leveraged proven #RLT expertise to help our sponsor meet or beat all critical milestones, securing #FDA approval in under four years. https://bit.ly/3Z4vydo #clinicaltrials #Radioligand #isotopes #clinicalresearch #psicro #radiopharmaceuticals #theranostic #diagnostic #imagingagents #oncology
Case Study: Phase 3 Radiopharmaceutical Clinical Trial in Oncology
https://psi-cro.com
To view or add a comment, sign in
-
GenFleet Therapeutics Fulzerasib has emerged as a strong contender in the treatment of KRAS G12C-mutated NSCLC, surpassing the efficacy of sotorasib and adagrasib. Its combination with cetuximab has shown exceptional promise, leading to plans for a Phase III trial. This highlights the potential for fulzerasib to become a key player in first-line therapy, pending further validation. Discover Expert Insights and In-Depth Analysis with DelveInsight Business Research LLP's Exclusive American Society of Clinical Oncology (ASCO) 2024 Coverage! https://lnkd.in/gQRnmPZ3 #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders
Fulzerasib Phase II KROCUS Study | ASCO 2024
delveinsight.com
To view or add a comment, sign in
-
The landscape of NSCLC treatment is evolving rapidly, and personalized medicine is at the forefront. Our latest blog post dives into a massive dataset of 80,000+ ALK, 35,000+ ROS1, 11,000+ EGFR, and more FISH results, shedding light on the prevalence of key mutations and the potential for more precise treatment plans. For pharmaceutical companies seeking to target clinicians and patients effectively, this data is a game-changer. Learn how these insights can revolutionize NSCLC care: https://bit.ly/3SkGEGT #NSCLC #PersonalizedMedicine #RealWorldData #PrognosHealth
Unveiling New Insights in NSCLC with Large-Scale FISH Panel Data
prognoshealth.com
To view or add a comment, sign in
26,422 followers